Estudo da influencia da acidez gastrica na farmacocinetica da furazolidona : implicações terapeuticas para a erradicação do Helicobacter pylori
AUTOR(ES)
Renato Agustin Mas Ortiz
DATA DE PUBLICAÇÃO
2001
RESUMO
Background: The administration of omeprazole may interfere with the absorption of orally administered drugs by reducing gastric pH and thus tablets dissolution.The aim of this study was to investigate the effects of a tive day administration of omeprazole on furazolidone pharmacokinetics. Methods: Eighteen healthy (male, female) volunteers were selected. The study had an open randomized two-period crossover design with a 21 day washout period between the phases. Plasma concentrations of furazolidone were measured by reversed-phase HPLC with ultraviolet detection. Results: Administration of omeprazole caused a signiticant reduction of Cmax (0.3426 .:t0.042 vs. 0.2440 .:t 0.046) and a not significant reduction of T1/2(4.869.:t 1.06 vs. 3.904 .:t 0.85 ) but did not interfere with other pharmacokinetic parameters of orally administered furazolidone. Conclusion: Our results indicate that furazolidone is well absorbed afier oral administration. Short-term treatment with omeprazole does not alter the bioavailablitity of furazolidone. The observed reduction in Cmaxand T1/2induced by acid blockade suggests a possible interference with the absorption kinetics of the drug
ASSUNTO(S)
farmacocinetica helicobacter pylori
ACESSO AO ARTIGO
http://libdigi.unicamp.br/document/?code=vtls000341803Documentos Relacionados
- Estudo sobre a influencia do pH gastrico na absorção de metronidazol : implicações clinicas para a erradicação do Helicobacter Pylori
- Furazolidona, tetraciclina e omeprazol: uma alternativa de baixo custo para erradicação de Helicobacter pylori em crianças
- Esquema quádruplo com furazolidona para retratamento do Helicobacter pylori, em pacientes ulcerosos
- Erradicação do Helicobacter pylori não influencia a doença do refluxo gastroesofágico: estudo prospectivo, paralelo, randomizado, aberto e controlado
- Omeprazol, Tetraciclina e Furazolidona, um tratamento para erradicação do H. pylori resistente em pacientes ulcerosos do Brasil